Fecal Occult Blood Test (FOBT) Market Set To Expand From $2.67 Billion In 2026: Growth Outlook Through 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Fecal Occult Blood Test (FOBT) Market Value Growth And Long-Term Outlook
The fecal occult blood test (FOBT) market size has shown significant expansion in recent years. It is anticipated to increase from $1.85 billion in 2025 to $1.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, this growth can be attributed to the rising prevalence of colorectal cancer, growing awareness of preventive health screening, expansion of national cancer screening programs, increasing geriatric population, and improvements in diagnostic laboratory infrastructure.
The fecal occult blood test (FOBT) market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $2.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected period include a surging demand for non-invasive diagnostic techniques, the increasing uptake of at-home testing solutions, escalating healthcare spending in developing economies, the broadening of personalized medicine strategies, and the greater incorporation of digital health platforms. Key trends anticipated during this forecast period involve the rising adoption of immunochemical FOBT kits, an increased inclination towards home-based screening examinations, an intensified emphasis on the early detection of colorectal cancer, the proliferation of point-of-care FOBT devices, and the accelerated development of high-sensitivity test reagents.
Get A Free Sample Report With In-Depth Market Insights:
Fecal Occult Blood Test (FOBT) Market Growth Backed By Core Demand Fundamentals
The rising occurrence and public health burden of colorectal cancer are anticipated to drive the expansion of the fecal occult blood test (FOBT) market in the future. Colorectal cancer, a malignancy originating in the colon or rectum, frequently evolves from unusual growths called polyps. Its increasing presence is linked to elements like inactive lifestyles, an aging demographic, and dietary patterns, all of which elevate the likelihood of cancer forming in the digestive system. The fecal occult blood test (FOBT) aids in screening for colorectal cancer by identifying concealed blood in stool early, thus allowing for prompt diagnosis, better treatment results, and slower disease advancement. As an example, the Office for National Statistics (ONS), a UK-based government department, reported in February 2025 that approximately 15,552 colorectal cancer deaths were recorded in England and Wales in 2023, with 2024 provisional data showing a comparable figure. This underscores the substantial impact of the disease and the heightened demand for early screening and preventative diagnostic instruments. Consequently, the growing incidence of colorectal cancer is stimulating the expansion of the fecal occult blood test (FOBT) market.
Fecal Occult Blood Test (FOBT) Market Segments: Where Is Growth Concentrated?
The fecal occult blood test (fobt) market covered in this report is segmented –
1) By Product Type: Guaiac-Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test, Other Product Types
2) By Sample Type: Stool-Based, Other Sample Types
3) By Application: Colorectal Cancer Screening, Gastrointestinal Bleeding, Other Applications
4) By End User: Hospitals, Diagnostic Laboratories, Clinics, Home Care Settings, Other End Users
Subsegments:
1) By Guaiac-Based Fecal Occult Blood Test: Manual Guaiac Test Kits, Automated Guaiac Test Systems, Point-Of-Care Guaiac Test Devices, High Sensitivity Guaiac Reagents
2) By Immunochemical Fecal Occult Blood Test: Qualitative Immunochemical Test Kits, Quantitative Immunochemical Test Systems, Point-Of-Care Immunochemical Devices, High Sensitivity Immunochemical Reagents
3) By Other Product Types: Deoxyribonucleic Acid-Based Fecal Occult Blood Test Kits, Enzyme Immunoassay Test Kits, Chromatographic Fecal Occult Blood Test Devices, Combination Fecal Occult Blood Test Systems
Fecal Occult Blood Test (FOBT) Market Growth Trends Reshaping The Competitive Landscape
Major companies operating in the fecal occult blood test (FOBT) market are concentrating on the development of innovative products, such as at-home over-the-counter (OTC) FOBT kits, to elevate early detection rates and enhance patient convenience. At-home over-the-counter (OTC) FOBT kits represent non-invasive testing options that empower individuals to collect stool samples at home for the purpose of detecting hidden blood, thereby aiding in early colorectal cancer screening and offering increased convenience compared to traditional lab-based tests. For instance, in December 2023, DiaCarta Inc., a US-based precision diagnostic company, launched the iColon Fecal Occult Blood Test, an OTC at-home test designed to enable the early identification of blood in stool, which is clinically relevant for both gastrointestinal disorders and colorectal cancer. The iColon test has been developed to be user-friendly and non-invasive, permitting patients to gather samples without the need for medical supervision. It integrates sensitive detection methods that enhance accuracy beyond conventional guaiac-based FOBTs, consequently reducing false negatives and facilitating earlier intervention. Additionally, it promotes timely follow-up with healthcare providers if abnormal results are found, contributing to proactive colorectal health management.
Fecal Occult Blood Test (FOBT) Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the fecal occult blood test (fobt) market are F. Hoffmann-La Roche AG, Siemens Healthineers AG, Medline Industries Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Quidel Corporation, Randox Laboratories Ltd., BIOMERICA Inc., Aidian Oy, Meridian Bioscience Inc., CTK Biotech Inc., Eiken Chemical Co. Ltd., Hemosure Inc., Alfa Scientific Designs Inc., AdvaCare Pharma Inc., Biohit Oyj, Immunostics Inc., Apacor Ltd., Humasis Co. Ltd., Firstep Bioresearch Inc., Biopanda Reagents Ltd, Ameritek Inc.
View The Full Fecal Occult Blood Test (FOBT) Market Report:
Fecal Occult Blood Test (FOBT) Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the fecal occult blood test (FOBT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal occult blood test (fobt) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
